Texas hospital CEO pleads guilty to role in multimillion-dollar pass-through payment scheme

FierceHealthcare | March 13, 2019

The former CEO of a small Texas hospital pleaded guilty to defrauding three of the state’s largest payers out of millions through a laboratory billing scheme. The Department of Justice announced that Harris Brooks, former CEO of Palo Pinto General Hospital in Mineral Wells, Texas, will face a prison sentence of up to five years and restitution payments for his role in the scheme. Brooks and co-conspirators took advantage of the hospital’s in-network deals with Cigna Texas, BlueCross BlueShield of Texas and UnitedHealthcare to use pass-through billing for laboratory services. Brooks and other participants and the scheme submitted billing for allergy and genetic tests they said were performed on-site at PPGH, according to DOJ. However, the hospital did not actually own the equipment for such tests, and patients were provided these services elsewhere.

Spotlight

The Centers for Medicare and Medicaid Services (CMS) defines accountable care organizations (ACOs) as groups of doctors, hospitals and other healthcare providers who come together voluntarily to give coordinated, high quality care to their Medicare patients.


Other News
FUTURE OF HEALTHCARE

Althea Expands Its Growing Broadband Coverage Area to Tacoma WA

Althea | March 26, 2022

Althea is proud to announce Tacoma, WA is the latest addition to its growing broadband coverage area, with installations and infrastructure investment focused in the Hilltop neighborhood. Founded in 2017, Althea’s mission is rooted in the belief that affordable broadband connectivity is a fundamental right for all people that strengthens communities, economic growth, educational opportunities, and healthcare access. Althea is a distributed Internet Service Provider which works together with local communities and network operators to provide sustainable high speed and low cost broadband access. This is made possible by Althea’s unique technology, infrastructure, and routing protocol. Althea’s routing protocol allows the service and accounting layers of the ISP to be almost entirely automated, and maximizes bandwidth utilization (i.e. delivers lower latency and higher speeds than one would typically experience from a given network connection, when compared to a traditional ISP routing protocol). This technology negates the need for contracts, late fees, and other drawbacks of traditional internet delivery. The mesh topology used to connect users also allows individuals to host infrastructure themselves, growing the network, and earning revenue share for doing so. This keeps value in the community, encourages community involvement, maintains low costs, and creates an ever more resilient network architecture. Althea uses a unique pay-as-you-go payment model, making it easy for users to manage costs. Additionally, each user has access to the always-on free tier, guaranteeing they will have access to no-cost basic internet, regardless of their financial situation. Unlike traditional ISPs, Althea’s technology does not artificially throttle bandwidth or utilize speed tiers either, so users always get the maximum speed their equipment is capable of delivering. Althea users in Tacoma can expect speeds around 100 Mbps and pay, on average, around $25/month. “Many people don’t have access to the internet, not because of availability, but costs and other barriers keep them from this vital resource.We believe internet access is a human right, which is why we provide an always-on, free tier of internet.” Deborah Simpier, Althea CEO and co-founder Hilltop, Tacoma was also one of the first proof-of-concept networks for Althea, partnering in 2020 with Tacoma Cooperative Network and the University of Washington to build and test community led LTE networks. Through this work in Open5GS, Althea developed KeyLTE, which is an embedded EPC inside an Althea home router, which provides flexibility to build and grow LTE/5G networks anywhere, quickly and affordably.

Read More

HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products: LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries. L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“ We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world. About L2Mtech Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de Media Contact: L2Mtech GmbH admin@L2Mtech.de +49 228 94730761

Read More

FUTURE OF HEALTHCARE

TRC Healthcare Expands Portfolio with the Acquisition of QURE Healthcare

TRC Healthcare | March 16, 2022

TRC Healthcare a trusted leader in continuing education, has acquired QURE Healthcare, a recognized innovator in clinical measurement and quality improvement. QURE's provider-focused solutions lead to better patient outcomes and lower costs for healthcare systems and coverage and reimbursement for life-science clients. TRC's acquisition paves the way for QURE to scale its innovative Clinical Performance and Value (CPV®) patient simulation software solutions. "Through the acquisition, TRC Healthcare intends to augment its already robust suite of products by focusing on improving patient outcomes with evidence-based training, education and continuing education/continuing medical education for physicians and other providers" TRC Healthcare's CEO,Wes Crews, announced. "QURE is excited to join a company that is so aligned with our mission to raise the quality of healthcare, standardize practice and lower costs by changing clinician behavior. Measuring and reducing care variation using CPV®vignettes is QURE's core business. We have demonstrated in the peer-review literature that we can do this from the ambulatory to the intensive care setting and for diseases ranging from angina to zoonoses, all with the goal to eliminate unwarranted variation, raise quality for patients and lower costs for payers." Dr.John Peabody, the founder and president of QURE TRC Healthcare regards QURE as another key addition to its recent acquisition of NetCE, an industry leading continuing education platform that educates nurses, physicians, and mental health professionals. Together, QURE and NetCE fortify the evidence-based healthcare solutions TRC offers, "The addition of QURE increases our link between strong education and better patient outcomes," remarkedWes Crews. Dr. Peabody will continue to serve as QURE's President and will take on the additional role of Chief Medical Officer at TRC Healthcare. Dr. Peabody is a renowned international health care figure in clinical care quality and a professor at theUniversity of California, San FranciscoandLos Angeles. In 2012, John started QURE Healthcare. The QURE platform – CPV® vignettes – has grown and become a widely adopted standard for measuring clinical practice. QURE CPVs are used by organizations looking to engage their providers in clinical variation reduction efforts, including large health care systems, independent practice associations, public and private payers, governments, non-governmental associations, and intergovernmental organizations. Dr. Peabody has contributed more than 200 articles, books, and abstracts to the peer-review literature, served on blue ribbon committees, testified before congress and advised heads of state on a wide variety of subjects notably quality improvement and the economic benefits of standardizing practice in healthcare systems. "QURE is an extraordinary company, with a validated product and team and an incredibly passionate community of users," saidWes Crews. "Together we can transform the way we engage providers and change patient care." About TRC Healthcare TRC Healthcare (TRC) is a premier source of lifelong learning solutions for healthcare professionals. TRC is most recognized for their education and CE offerings within the highly-regarded Pharmacist's Letter, Prescriber's Letter, and Pharmacy Technician's Letter. TRC also offers Pharmacy Technicians University, the leading online training program for pharmacy technicians. The Natural Medicines database makes it easy for subscribers to find unbiased, evidenced-based research about alternative drug therapies. Through the acquisition of CriticalPoint, NetCE and Bula TRC Healthcare has been expanding its offerings. CriticalPoint increases patient safety through a variety of educational compounding offerings concentrating on USP 797, 800, and 795. NetCE is an industry-leading, continuing- education platform supporting multiple professions including nurses, physicians, and mental health. And Bula provides legal and regulatory advice to retail pharmacies. These additions give TRC Healthcare the industry's largest catalog of continuing education and advisory services, with thousands of courses trusted by healthcare professionals to provide accredited training that meets continuing education and licensing requirements. About QURE QURE Healthcare is a provider engagement company committed to improving the quality of clinical care. using its proprietary technology, CPV®(Clinical Performance and Value) vignettes. CPV®vignettes

Read More

HEALTH TECHNOLOGY

HCL Technologies and NEORIS Sign Agreement for Integrated IT Services

HCL Technologies | March 23, 2022

HCL Technologies a leading global technology company, has signed a collaboration agreement with NEORIS, a leading global digital accelerator that co-creates disruptive solutions for digitally aspirational companies. The agreement will bring unique capabilities to clients in global markets, including the ability to increase application usage time, business management operations and integrated IT services. As a result of this collaboration, both companies will be able to expand their operations and access new markets, making them better positioned to explore global markets. NEORIS, with more than 20 years of experience and global presence including operations in Latin America, will strengthen HCL’s presence in territories like Mexico and South America which offer great opportunities for commercial development. With operations in 52 countries, HCL Technologies will aid NEORIS in expanding its business internationally, primarily in the United States, Europe and Asia. Together, NEORIS and HCL Technologies can speed up digital transformation, mitigate risks, empower teams based on product development, create a zero-incident culture and save costs. The solutions that NEORIS and HCL will offer together will focus on complementing approaches and solutions, new technologies and talent development among other areas of expertise. "HCL Technologies and NEORIS will work together to find new business opportunities in a united effort, one where NEORIS will provide the best talent with the best skills in the market to reduce costs, time and risk. We have positioned our centers of excellence to scale and meet the expectations of each business and deliver value. Our partnership enables us to provide the best services and solutions to our clients while positioning them for future success." Marcelo Costa, global head of strategic alliances at NEORIS "We are delighted to offer this unique program to our clients in Latin America who are seeking ways to optimize their teams through best-in-class technology solutions," said Ajay Bahl, corporate vice president, HCL Technologies. "Our collaboration will also contribute to our continuous effort to build a great talent pool in Mexico to deliver industry-best service and capabilities to our customers." About NEORIS NEORIS is a leading global digital accelerator that co-creates disruptive solutions for companies that digitally aspire to increase their connections with customers, employees and stakeholders. The company is made of creative teams with technical experience and deep knowledge of their sectors. Headquartered in Miami, Florida, NEORIS has a network of global delivery centers, design studios, and operations in the United States, Europe, Latin America and India. More information is available at www.NEORIS.com, LinkedIn, and Twitter. About HCL Technologies HCL Technologies (HCL) empowers global enterprises with technology for the next decade, today. HCL’s Mode 1-2-3 strategy, based on its deep-domain industry expertise, customer-centricity and entrepreneurial culture of Ideapreneurship™, enables businesses to transform into next-gen enterprises. HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in the areas of applications, infrastructure, digital process operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering HCL Technologies (HCL) empowers global enterprises with technology for the next decade, today. HCL’s Mode 1-2-3 strategy, based on its deep-domain industry expertise, customer-centricity and entrepreneurial culture of Ideapreneurship™, enables businesses to transform into next-gen enterprises. HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in the areas of applications, infrastructure, digital process operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering

Read More

Spotlight

The Centers for Medicare and Medicaid Services (CMS) defines accountable care organizations (ACOs) as groups of doctors, hospitals and other healthcare providers who come together voluntarily to give coordinated, high quality care to their Medicare patients.

Resources